Gaithersburg, MD, June 11, 2015  – MaxCyte® Inc., the pioneer in cell therapies using scalable, highperformance cell transfection systems, announced today that it has been awarded a grant of $0.5M from the Maryland Stem Cell Research Fund (MSCRF). The grant, entitled “Development of a non-viral, site-specific, ex vivo gene-modified cell therapy as treatment for CGD”, will support the conduct of preclinical studies, in collaboration with the Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The studies are designed to develop processes and clinical scale protocols using MaxCyte’s cGMP-compliant Flow Electroporation technology for the correction of genetic mutations in patient-derived CD34+ hematopoietic stem cells as a potential treatment for Chronic Granulomatous Disease (CGD).


“We are honored to receive this grant from MSCRF,” said Douglas A. Doerfler, Founder, President and CEO of MaxCyte, “This grant will provide critical resources to advance our work in development of novel cell-based medicines as potential treatments for patients with genetic diseases.”


“We are happy to support MaxCyte’s translational work on gene-modified cell therapy for treatment of genetic diseases” said Dr. Dan Gincel, Executive Director of the Maryland Stem Cell Research Fund. “Our awards help fund a diverse range of research and we are particularly pleased to support organizations advancing regenerative medicine.”


About the Maryland Stem Cell Research Fund

The Maryland Stem Cell Research Fund (MSCRF) was established by the State of Maryland under the Maryland Stem Cell Research Act of 2006 to promote State-funded stem cell research and cures through grants and loans to public and private entities in the State. Administered by the Maryland Technology Development Corporation (TEDCO), the MSCRF is overseen by an independent commission that sets policy and develops criteria, standards and requirements for applications to the Fund. The current MSCRF budget for FY2016 is $9.4 million.

For more information about the Maryland Stem Cell Research Fund and a list of Commission members, please visit:


About MaxCyte

MaxCyte is the leader in advancing life-changing therapeutics with flow electroporation. MaxCyte’s best in class cell modification technology is used in the discovery, development, and manufacture of small molecule, biologic, and cell-based medicines. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of (co)transfected cells for cellular therapy, genetic engineering, protein and antibody production, rapid response vaccine development, and cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale. In addition to being used in 9 out of the top 10 companies worldwide, MaxCyte currently has clinical, preclinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.

For more information visit /